Showing results (1631-1640 of 1,838) with videos related to

Sort By:
Pageof 184
American Heart Journal|April 1, 2009
Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HFClyde W Yancy, Gregg C Fonarow, Nancy M Albert, et al.
The American Journal of Cardiology|April 13, 2010
Influence of renal function on the use of guideline-recommended therapies for patients with heart failureJ Thomas Heywood, Gregg C Fonarow, Clyde W Yancy, et al.
Frontiers in Cardiovascular Medicine|January 26, 2024
Harnessing the power of RNA therapeutics in treating ischemic heart failure: the TRAIN-HEART storyAlba M Albert, Deepak Balamurali, Evangelia Beslika, et al.
Research Square|April 16, 2025
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of the Muscarinic M 1 Positive Allosteric Modulator VU0467319 for Alzheimer's disease: A Single Ascending-Dose Study in Healthy ParticipantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Neuroimage|May 22, 2009
Regionally-specific diffusion tensor imaging in mild cognitive impairment and Alzheimer's diseaseM M Mielke, N A Kozauer, K C G Chan, et al.
American Heart Journal|April 6, 2010
Electronic health records and quality of care for heart failureMary Norine Walsh, Clyde W Yancy, Nancy M Albert, et al.
JACC. Clinical Electrophysiology|January 24, 2020
Circulating miRNAs and Risk of Sudden Death in Patients With Coronary Heart DiseaseMichael G Silverman, Ashish Yeri, M Vinayaga Moorthy, et al.
Oncogene|September 12, 2012
Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesisW Ketchart, K M Smith, T Krupka, et al.
Alzheimer'S Research & Therapy|July 2, 2025
Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M<sub>1</sub> positive allosteric modulator VU0467319 for Alzheimer's disease: a single ascending-dose study in healthy participantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
British Journal of Pharmacology|July 3, 2007
Neuroprotective and anticonvulsant effects of EGIS-8332, a non-competitive AMPA receptor antagonist, in a range of animal modelsG Gigler, K Móricz, M Agoston, et al.
Pageof 184